老年全膝或全髋关节置换术围手术期使用加巴喷丁类药物与术后长期阿片类药物使用风险
基于2011至2018年Medicare索赔数据,纳入52788例≥65岁初次全膝或全髋关节置换术且术前无长期阿片类药物使用的患者。围手术期使用加巴喷丁类药物者占7.5%。调整混杂因素后,围手术期使用加巴喷丁类药物与术后长期阿片类药物使用风险无显著关联(RR=1.07,95%CI 0.91-1.26,P=0.408)。
要点
- 老年初次全膝或全髋关节置换患者中,围手术期加巴喷丁类药物使用率为7.5%。
- 术后长期阿片类药物使用率:使用组3.8%,未使用组4.0%。
- 调整后围手术期加巴喷丁类药物使用与术后长期阿片类药物使用风险无显著关联(RR=1.07,95%CI 0.91-1.26,P=0.408)。
核心结论
- 在老年Medicare受益者中,初次全膝或全髋关节置换术围手术期使用加巴喷丁类药物与术后长期阿片类药物使用风险降低或增加均无显著关联。
研究设计与样本
- 基于2011至2018年Medicare索赔数据的回顾性队列研究,纳入≥65岁因初次全膝或全髋关节置换住院且术前无长期阿片类药物使用的按服务收费受益者,围手术期加巴喷丁类药物使用定义为入院前7天至出院后7天,要求围手术期接受阿片类药物,从出院后第7天随访180天评估术后长期阿片类药物使用(连续≥90天),采用改良泊松回归并通过倾向评分加权调整混杂因素。
主要发现
- 共纳入52788例符合条件者(平均年龄72.7岁,标准差5.3;女性62.5%;白人89.7%),其中3967例(7.5%)围手术期接受加巴喷丁类药物。
- 术后长期阿片类药物使用率:围手术期使用加巴喷丁类药物组为3.8%,未使用组为4.0%。
- 调整混杂因素后,围手术期使用加巴喷丁类药物组与未使用组术后长期阿片类药物使用风险相似(RR=1.07;95%CI 0.91-1.26,P=0.408)。
- 敏感性和偏倚分析结果一致。
关键数值与推荐
- 术后长期阿片类药物使用定义为连续≥90天。
- 围手术期加巴喷丁类药物使用测量窗口为入院前7天至出院后7天。
- 随访从出院后第7天开始持续180天。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Gabapentinoids are recommended by guidelines as a component of multimodal analgesia to manage postoperative pain and reduce opioid use. It remains unknown whether perioperative use of gabapentinoids is associated with a reduced or increased risk of postoperative long-term opioid use (LTOU) after total knee or hip arthroplasty (TKA/THA). METHODS: Using Medicare claims data from 2011 to 2018, we identified fee-for-service beneficiaries aged ≥ 65 years who were hospitalized for a primary TKA/THA and had no LTOU before the surgery. Perioperative use of gabapentinoids was measured from 7 days preadmission through 7 days postdischarge. Patients were required to receive opioids during the perioperative period and were followed from day 7 postdischarge for 180 days to assess postoperative LTOU (ie, ≥90 consecutive days). A modified Poisson regression was used to estimate the relative risk (RR) of postoperative LTOU in patients with versus without perioperative use of gabapentinoids, adjusting for confounders through propensity score weighting. RESULTS: Of 52,788 eligible Medicare older beneficiaries (mean standard deviation [SD] age 72.7 [5.3]; 62.5% females; 89.7% White), 3,967 (7.5%) received gabapentinoids during the perioperative period. Postoperative LTOU was 3.8% in patients with and 4.0% in those without perioperative gabapentinoids. After adjusting for confounders, the risk of postoperative LTOU was similar comparing patients with versus without perioperative gabapentinoids (RR = 1.07; 95% confidence interval [CI] = 0.91-1.26, P = .408). Sensitivity and bias analyses yielded consistent results. CONCLUSION: Among older Medicare beneficiaries undergoing a primary TKA/THA, perioperative use of gabapentinoids was not associated with a reduced or increased risk for postoperative LTOU.
引用
- Chen C, Tighe PJ, Lo-Ciganic WH, et al. Perioperative Use of Gabapentinoids and Risk for Postoperative Long-Term Opioid Use in Older Adults Undergoing Total Knee or Hip Arthroplasty. J Arthroplasty. 2022. PMID: 35577053. doi:10.1016/j.arth.2022.05.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。